Concert Pharmaceuticals

September 03, 2019

Concert squares up to Pfizer in alopecia Jak bout

Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.

February 26, 2019

Xeljanz warning Jaks up safety concerns

An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.

September 21, 2018

Upcoming events – Phase II readouts loom for Concert and Reata

Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.

October 25, 2017

Abbvie’s Jak flashes a warning for the whole class

March 29, 2017

Vertex investors toast birth of the son of Orkambi

March 06, 2017

Vertex’s cystic fibrosis strategy in tune with Concert buy

December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

June 10, 2015

Sage advice takes Marinus higher

March 31, 2015

Daily Market Movers (30 Mar 2015)

April 03, 2014

Biotech floats hint at a narrowing gap between perception and reality

April 01, 2014

Biotech’s record-breaking quarter shines spotlight on sustainability

Load More